Industry News

- Read more about Hep C infected livers offer similar outcomes to healthy livers in those waiting for liver transplant
Data from a new study presented today may help reduce the waiting time for a liver transplant for people with the Hepatitis C virus (HCV). The study, presented at The International Liver Congress™ 2016 in Barcelona, Spain, demonstrated that the medium to long-term outcomes for people with HCV who have received a HCV-positive liver were no different from those who were given a healthy liver.
- Read more about Researchers uncover earliest events following HIV infection, before virus is detectable
New research in monkeys exposed to SIV, the animal equivalent of HIV, reveals what happens in the very earliest stages of infection, before virus is even detectable in the blood, which is a critical but difficult period to study in humans. The findings, published online today in the journal Cell, have important implications for vaccine development and other strategies to prevent infection.
- Read more about CDC Concludes Zika Causes Microcephaly and Other Birth Defects
Scientists at the Centers for Disease Control and Prevention (CDC) have concluded, after careful review of existing evidence, that Zika virus is a cause of microcephaly and other severe fetal brain defects. In the report published in the New England Journal of Medicine, the CDC authors describe a rigorous weighing of evidence using established scientific criteria.
- Read more about Addex reports positive results of mGlu5 receptor occupancy study with dipraglurant in healthy volunteers
Addex Therapeutics announced the results of the mGlu5 receptor occupancy study with dipraglurant in healthy volunteers. The study was conducted under the direction of lead investigator professor of neurology, Dean F. Wong, MD, PhD of the Departments of Radiology, Psychiatry and Neuroscience at Johns Hopkins University.
- Read more about Mylan launches first and only available intermediate dosage strengths of Generic Lopressor® tablets 37.5 mg and 75 mg
Mylan N.V. announced the U.S. launch of Metoprolol Tartrate Tablets USP, 37.5 mg and 75 mg, which is the generic version of Novartis' Lopressor® Tablets. These strengths are the first and only available intermediate dosage strengths between the existing Metoprolol Tartrate Tablets USP strengths of 25 mg, 50 mg and 100 mg. Mylan currently is the only manufacturer that offers Metoprolol Tartrate Tablets in five strengths.
- Read more about Over-the-counter drug may reverse chronic vision damage caused by multiple sclerosis
A common antihistamine used to treat symptoms of allergies and the common cold, called clemastine fumarate, partially reversed damage to the visual system in people with multiple sclerosis (MS) in a preliminary study released today that will be presented today at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
- Read more about Scientists discover how chinese medicinal plant makes anti-cancer compound
New research led by Professor Cathie Martin of the John Innes Centre has revealed how a plant used in traditional Chinese medicine produces compounds which may help to treat cancer and liver diseases.
- Read more about How depression may compound risk of type 2 diabetes
Depression, metabolic factors combine to boost risk of developing diabetes, study findsDepression may compound the risk of developing type 2 diabetes in people with such early warning signs of metabolic disease as obesity, high blood pressure and unhealthy cholesterol levels, according to researchers from McGill University, l'Université de Montréal, the Institut de recherches cliniques de Montréal and the University of Calgary.
- Read more about Growing AD population driving market, raising treatment urgency, says BCC research
The increasing incidence of Alzheimer's disease (AD), improving diagnostic technologies and the prospect of new therapies are driving the global AD market. BCC Research reveals in its new report the need for effective treatments has become more urgent, especially given the recurrent failure of several prominent disease-modifying agents in late-stage development.
- Read more about AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer’s disease
AstraZeneca and Eli Lilly and Company announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for early Alzheimer’s disease, will continue into Phase III of the Phase II/III seamless trial.